Qbrexza is an FDA-approved, brand-name topical medication for axillary hyperhidrosis that genuinely works. The clinical evidence is solid, the mechanism is well-understood, and for patients with adequate insurance coverage, it's a reasonable therapeutic choice. The problem, for most patients, is cost: without insurance, Qbrexza runs $600–$800 per month out of pocket.
Compounded glycopyrronium is the same active drug:the same molecules blocking the same muscarinic receptors on sweat glands:available from a licensed compounding pharmacy at a fraction of the cost. For patients paying out of pocket, it's often the only realistic path to glycopyrronium treatment.
This article walks through the clinical and practical differences so you can make an informed decision. The short version: they contain the same drug. The regulatory status is different. The cost is dramatically different. Quality depends heavily on the compounding pharmacy.
What Is Qbrexza?
Qbrexza (glycopyrronium tosylate) is the brand-name, FDA-approved formulation for primary axillary hyperhidrosis. It was approved by the FDA in 2018 and is manufactured by Dermira, now owned by Eli Lilly. The drug is available as a pre-moistened cloth wipe applied to each armpit once daily, usually in the evening before sleep.
The clinical evidence supporting Qbrexza comes from two large Phase 3 randomized controlled trials: ATMOS-1 and ATMOS-2, which enrolled 697 total patients in a placebo-controlled design. The results were meaningful: patients treated with Qbrexza showed significant reductions in axillary sweating compared to placebo, as measured by multiple endpoints including gravimetric sweat production, the Hyperhidrosis Disease Severity Scale (HDSS), and Dermatology Life Quality Index (DLQI) scores. The effect was sustained over the trial period, and the side effect profile was favorable relative to other anticholinergic options:dry mouth occurred in approximately 6% of trial participants, with urinary hesitancy and constipation occurring less frequently.
The wipe formulation is standardized and consistent: each wipe contains a fixed amount of active ingredient and preservatives, applied directly to dry underarm skin. This is a finished pharmaceutical product that has undergone the full FDA new drug application (NDA) process, which includes manufacturing oversight, quality assurance, stability testing, and post-market surveillance.
What Is Compounded Glycopyrronium?
Compounded glycopyrronium bromide is the same drug in a different form, created by a licensed 503A compounding pharmacy to your prescription. Instead of a pre-moistened wipe, it's typically formulated as a topical gel, solution, or cream that you apply directly to the affected area:usually the underarms, but it can be compounded for palmar, plantar, or facial hyperhidrosis as well.
The key distinction: compounded glycopyrronium is not an FDA-approved finished drug product. However, the active ingredient:glycopyrronium:is an FDA-approved molecule (it's been used for decades in other formulations, like oral glycopyrrolate for systemic anticholinergic effects). Pharmaceutical compounding is legal and regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act. A licensed compounding pharmacy fills a prescription from a prescriber, sources pharmaceutical-grade ingredients, and compounds them according to USP (United States Pharmacopeia) standards.
The compounded version offers flexibility: your prescriber can specify the concentration, base formulation (gel, lotion, solution), and volume to match your needs. It's made fresh, not mass-manufactured, and can be adjusted if your response changes over time.
The Clinical Comparison
From a pharmacological standpoint, Qbrexza and compounded glycopyrronium are essentially equivalent. Both contain glycopyrronium as the active ingredient:the tosylate salt in Qbrexza versus the bromide salt in the compounded formulation. This salt form difference is pharmacokinetically insignificant: both dissociate to deliver the same active molecule that blocks muscarinic receptors on eccrine sweat glands.
The mechanism is identical. Glycopyrronium binds to muscarinic-3 (M3) receptors on the secretory cells of eccrine sweat glands, blocking the acetylcholine signal that triggers perspiration. The effect is local:topical application means minimal systemic absorption:and the drug doesn't cross the blood-brain barrier significantly, which is one reason it has a lower dry mouth burden than oxybutynin.
The evidence base is where they diverge slightly. Qbrexza has direct Phase 3 RCT data from the ATMOS trials. Compounded glycopyrronium doesn't have its own standalone RCT:it relies on the same evidence base for the glycopyrronium drug class. That said, the pharmacology is identical, and prescribers have used compounded glycopyrronium for axillary hyperhidrosis in clinical practice with consistent, documented good outcomes.
Formulation consistency is the practical difference. Qbrexza is a standardized product: every wipe is identical in concentration and application. Compounded glycopyrronium concentration, base, and formulation can vary by pharmacy and prescription:the quality depends entirely on the compounding pharmacy's adherence to USP standards, sterility practices, and ingredient sourcing. A reputable compounding pharmacy with quality controls and third-party testing is essential.
The Cost Reality
This is where the practical decision tree diverges sharply for most patients.
Qbrexza without insurance costs approximately $600–$900 per month at retail. With good commercial insurance and a manufacturer coupon, the copay can be significantly reduced:sometimes to $50–$100:but this requires that your insurance covers hyperhidrosis treatment (many don't, classifying it as cosmetic) and that prior authorization is approved (which is not guaranteed). Insurance coverage is inconsistent, and prior authorizations are frequently denied.
Compounded glycopyrronium typically costs $40–$80 per month depending on the pharmacy, formulation, and quantity prescribed. For a patient paying out of pocket, this is often the difference between accessible treatment and unaffordable treatment.
Insurance coverage for Qbrexza has improved in recent years, but coverage remains patchy and often requires prior auth. If your insurance does cover it without significant barriers, Qbrexza is a reasonable choice. If you're uninsured or self-pay, or if your insurance denies coverage, compounded glycopyrronium is the realistic path to this drug.
How to Think About the Decision
If you have strong insurance coverage for Qbrexza: The FDA-approved finished product is a valid choice. You get standardized formulation, direct clinical trial evidence, and regulatory oversight of the manufacturing process. If your copay is reasonable and prior authorization is likely to be approved, there's no clinical reason to avoid it.
If you're paying out of pocket or your insurance denies coverage: Compounded glycopyrronium offers the same active drug at a fraction of the cost. The evidence base for the drug itself is robust:it's the same molecule that was tested in the ATMOS trials. The key is using a reputable, licensed compounding pharmacy that follows USP standards and has quality controls in place. Ask your pharmacy about concentration testing, sterility assurance, and stability data.
Quality of the compounding pharmacy matters. Not all compounding pharmacies are equal. Ask your prescriber for a referral to a pharmacy they trust, or ask the pharmacy directly about their USP <797> standards compliance (for non-sterile products, this is less critical, but it indicates rigor), their testing practices, and their ingredient sourcing. Sere partners with vetted compounding pharmacies that meet these standards.
The clinical outcomes are comparable when the compounded product is made by a quality pharmacy. The main difference you'll notice is the formulation:you're applying a gel or solution rather than a wipe:which is a minor adjustment. Both work.
Side-by-Side Comparison
| Feature | Qbrexza | Compounded Glycopyrronium |
|---|---|---|
| Active Ingredient | Glycopyrronium tosylate | Glycopyrronium bromide |
| FDA Approval Status | Approved as finished product | Compounded from approved ingredient |
| Evidence Base | Phase 3 ATMOS trials (697 patients) | Drug-class evidence + clinical use |
| Out-of-Pocket Cost | $600–$900/month | $40–$80/month |
| Formulation | Pre-moistened wipe | Topical gel, solution, or cream |
| Pharmacology | Identical muscarinic antagonist effect | Identical muscarinic antagonist effect |
| Side Effect Profile | Dry mouth ~6%, urinary hesitancy, constipation | Dry mouth ~6%, urinary hesitancy, constipation |
| Best For | Insured patients with approved coverage | Uninsured or self-pay patients; can tailor formulation |